Program
rimegepant
Also written as “Rimegepant”, “BMS-927711 (CGRP Antagonist)” and “Rimegepant (PF-07899801)”.
Its studies are mostly in Migraine Disorders · Nasal Polyps · Trigeminal Neuralgia · Temporomandibular Joint Disorders, led by Pfizer.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 278 open or running | phase 4since Jan 12, 2022 | Sep 7, 2011 | Nov 29, 2026phase 3 · NCT06641466 |
Also a collaborator on its studies: bioshin-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Sep 7, 2011.
- Nov 19, 2021Phase 3 study in Migraine DisordersNCT05156398 · 640 planned · United States, Canada, France and more
- Jan 12, 20222 phase 4 studies in Migraine DisordersNCT05207865, NCT05217927
- Jan 31, 2022Phase 3 study in Chronic Rhinosinusitis (CRS) With and Without Nasal PolypsNCT05248997 · 261 enrolled · United States
- Feb 21, 2022Phase 3 study in Temporomandibular Joint DisordersNCT05262517 · 126 enrolled · United States
- Mar 23, 2022Phase 3 study in Migraine DisordersNCT05371652 · 241 enrolled · China
- May 27, 20222 phase 3 studies in Migraine DisordersNCT05399485, NCT05399459
- Aug 18, 20222 phase 4 studies in Migraine DisordersNCT05509400, NCT05518123
- Mar 30, 2023Phase 3 study in Migraine DisordersNCT05810038 · 787 enrolled · China
- Sep 24, 2024Phase 3 study in Migraine DisordersNCT06616194 · 636 enrolled · United States, Canada, China and more
- Oct 11, 2024Phase 3 study in Menstrual MigraineNCT06641466 · 723 planned · United States, Argentina, Canada and more
- May 20, 2026Phase 4 study in Acute Treatment of MigraineNCT07609914 · 400 planned · United States, Israel
- Jun 29, 2026Phase 4 study in Migraine DisordersNCT07685769 · 60 planned · India
- Jul 22, 2026Phase 3 study in Preventive Treatment of MigraineNCT07729462 · 400 planned · United States, Israel
- Oct 23, 2026Primary completion moved from 2028-08-19 to 2030-02-26Date moved laterphase 3 · +18 months · NCT06616194
Ahead
- Nov 29, 2026Primary completion: phase 3 study in Menstrual MigraineNCT06641466
- Jan 4, 2028Primary completion: phase 4 study in Migraine DisordersNCT07685769
- Jun 7, 2028Primary completion: phase 4 study in Acute Treatment of MigraineNCT07609914
- Oct 21, 2028Primary completion: phase 3 study in Preventive Treatment of MigraineNCT07729462
TargetBeta
“Calcitonin gene-related peptide type 1 receptor antagonist; Calcitonin gene-related peptide type 1 receptor antagonist”ChEMBL 37, by rule
Other programs on CALCRL
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| atogepantrule | AbbVie | phase 4 | 19 |
| ubrogepantrule | AbbVie | phase 4 | 13 |
| zavegepantrule | Pfizer | phase 3 | 13 |
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07729462Preventive Treatment of Migraine · United States, Israel | 3 | Recruiting | Oct 21, 2028 | 400 |
| NCT07685769Migraine Disorders · India | 4 | Recruiting | Jan 4, 2028 | 60 |
| NCT07609914Acute Treatment of Migraine · United States, Israel | 4 | Recruiting | Jun 7, 2028 | 400 |
| NCT06641466Menstrual Migraine · United States, Argentina, Canada and more | 3 | Recruiting | Nov 29, 2026 | 723 |
| NCT06616194Migraine Disorders · United States, Canada, China and more | 3 | Active, not recruiting | Feb 26, 2030 | 636 |
| NCT05810038Migraine Disorders · China | 3 | Completed | Aug 25, 2025 | 787 |
| NCT05518123Migraine Disorders · United States, Australia, Austria and more | 4 | Completed | Mar 31, 2025 | 962 |
| NCT05509400Migraine Disorders · United States, Australia, Austria and more | 4 | Completed | Mar 10, 2025 | 813 |
| NCT05399485Migraine Disorders · Japan | 3 | Completed | Jan 18, 2024 | 496 |
| NCT05399459Migraine Disorders · Japan | 3 | Completed | Jan 19, 2024 | 897 |
| NCT05371652Migraine Disorders · China | 3 | Completed | Feb 6, 2024 | 241 |
| NCT05262517Temporomandibular Joint Disorders · United States | 3 | Terminated | May 18, 2023 | 126 |
| NCT05248997Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps · United States | 3 | Completed | Mar 11, 2024 | 261 |
| NCT05217927Migraine Disorders · United States, Austria, Canada and more | 4 | Completed | Oct 22, 2024 | 1,415 |
| NCT05207865Migraine Disorders · United States | 4 | Completed | Jul 2, 2024 | 441 |
| NCT05156398Migraine Disorders · United States, Canada, France and more | 3 | Recruiting | Mar 27, 2029 | 640 |
| NCT04743141Migraine Disorders · United States, Poland, Spain | 3 | Recruiting | Jul 31, 2030 | 600 |
| NCT04649242Migraine Disorders · United States, Canada, China and more | 3 | Recruiting | Jan 9, 2029 | 2,100 |
| NCT04574362Migraine Disorders · China, Korea, Republic of | 3 | Completed | Nov 24, 2021 | 1,648 |
| NCT03941834Trigeminal Neuralgia · United States | 2 | Terminated | May 11, 2023 | 65 |
| NCT03732638Migraine Disorders · United States | 3 | Completed | Dec 10, 2019 | 1,590 |
| NCT03461757Migraine Disorders · United States | 3 | Completed | Oct 8, 2018 | 1,811 |
| NCT03266588Migraine Disorders · United States | 3 | Completed | Jul 15, 2019 | 3,019 |
| NCT03237845Migraine Disorders · United States | 3 | Completed | Jan 25, 2018 | 1,499 |
| NCT03235479Migraine Disorders · United States | 3 | Completed | Jan 21, 2018 | 1,485 |
| NCT01445067Migraine Disorders · United States | 1 | Completed | Sep 2012 | 48 |
| NCT01430442Migraine Disorders · United States | 2 | Completed | May 2012 | 1,026 |
How it is read
Names in the registry
- “Rimegepant”, 21 entries
- “BMS-927711 (CGRP Antagonist)”, 2 entries
- “Rimegepant (PF-07899801)”, 1 entry
- “Rimegepant/BHV3000”, 1 entry
- “Rimegepant 75 mg ODT”, 1 entry
Conditions, from the studies’ own filings
- Migraine Disorders, 24 studies
- Nasal Polyps, 1 study
- Trigeminal Neuralgia, 1 study
- Temporomandibular Joint Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.